SUMMIT, NJ (TheStreet) --European regulators have rejected Celgene's request for an expanded approval of its multiple myeloma drug Revlimid to treat newly diagnosed patients, a stunning setback that slams the brakes on the company's growth. Celgene shares were down $8, or 12%, to $59.15 in early Thursday trading. Investors were widely expecting Celgene to announce expanded European regulatory ...
